NYXH
Nyxoah SA

379
Mkt Cap
$195.34M
Volume
10,508.00
52W High
$11.87
52W Low
$4.35
PE Ratio
-1.83
NYXH Fundamentals
Price
$4.71
Prev Close
$4.54
Open
$4.61
50D MA
$5.24
Beta
0.56
Avg. Volume
67,969.74
EPS (Annual)
-$1.96
P/B
2.85
Loading...
Loading...
News
all
press releases
Cantor Fitzgerald Raises Earnings Estimates for Nyxoah
Nyxoah SA (NASDAQ:NYXH - Free Report) - Research analysts at Cantor Fitzgerald boosted their FY2025 earnings estimates for shares of Nyxoah in a report released on Wednesday, November 19th. Cantor...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Nyxoah (NASDAQ:NYXH) Posts Quarterly Earnings Results, Misses Expectations By $0.13 EPS
Nyxoah (NASDAQ:NYXH - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by...
MarketBeat·11d ago
News Placeholder
Nyxoah SA (NYXH) Reports Q3 Loss, Beats Revenue Estimates
Nyxoah (NYXH) delivered earnings and revenue surprises of -21.31% and +18.02%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·12d ago
News Placeholder
Enovis (ENOV) Q3 Earnings and Revenues Beat Estimates
Enovis (ENOV) delivered earnings and revenue surprises of +11.94% and +2.41%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·19d ago
News Placeholder
10x Genomics (TXG) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·26d ago
News Placeholder
Analysts Estimate Nyxoah SA (NYXH) to Report a Decline in Earnings: What to Look Out for
Nyxoah (NYXH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·27d ago
News Placeholder
Nyxoah Shares Rise on First U.S. Commercial Use of Genio System
NYXH's first U.S. commercial use of its Genio system signals strong physician demand and sets the stage for broad adoption in sleep apnea care.
Zacks·2mo ago
News Placeholder
US-Listed Nyxoah Shares Soar On First Genio System Implants In Patients With Sleep Disorder
Nyxoah CEO Olivier Taelman said that the company has also trained surgeons, obtained Value Analysis Committee approvals, and achieved successful coverage from major payors.
Stocktwits·2mo ago
News Placeholder
Nyxoah Expands in the Middle East to Provide Wider Access to Genio
NYXH expands in the Middle East after Abu Dhabi's first Genio implant, aiming to broaden access for OSA patients.
Zacks·2mo ago
News Placeholder
Nyxoah Secures FDA Clearance for Genio System to Treat Sleep Apnea
NYXH wins FDA approval for its leadless, battery-free Genio sleep apnea therapy, backed by strong trial results.
Zacks·3mo ago

Latest NYXH News

View

Advertisement|Remove ads.

Advertisement|Remove ads.